Nasdaq · CIK 0001997296
MDCX Medicus Pharma Ltd.
Insider trading from SEC Form 4. Last filing 35 d ago. Close $4.60 on Oct 9, 2026, 0% from the 52-week low and -10% from the high.
In brief
Medicus Pharma Ltd. (MDCX) has 57 SEC Form 4 filings on file from 15 insiders, the latest filed on Sep 8, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
1 open-market trade has been scored at MDCX. The newest: Velocity Fund Partners, LP (10% owner) sold $579k of stock on May 20, 2025, filed May 21, 2025, scored 31 (weak).
1 Form 144 notice of planned sales is on file, the latest filed May 20, 2025.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Medicus Pharma Ltd., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 31Weak | Velocity Fund Partners, LP owner sell | $579k 75,000 shares | -2% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| May 20, 2025 | VELOCITY FUND PARTNERS, LP Major Shareholders | 118,000 1.00% of outstanding | $23M | May 20, 2025 | none |
Transactions
The newest 50 of 65 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 4, 2026 | Edward J. Brennan Chief Scientific Officer | AGrant or award Common Shares, no par value | +588,235 | $0.17 | $100k | 674,735 | 35 d ago |
| Sep 4, 2026 | Raza Bokhari Chief Executive Officer | AGrant or award Common Shares, no par value | +2,941,176 | $0.17 | $501k | 2,941,176 | 35 d ago |
| Sep 4, 2026 | Carolyn F. Bonner President and CFO | AGrant or award Common Shares, no par value | +1,470,588 | $0.17 | $251k | 1,489,493 | 35 d ago |
| Sep 4, 2026 | Faisal Mehmud Chief Medical Officer | AGrant or award Common Shares, no par value | +1,470,588 | $0.17 | $251k | 1,470,588 | 35 d ago |
| Sep 4, 2026 | Andrew Alasdair Smith Chief Operating Officer | AGrant or award Common Shares, no par value | +735,294 | $0.17 | $125k | 735,458 | 35 d ago |
| Sep 4, 2026 | Andrew Alasdair Smith Chief Operating Officer | AGrant or award Stock Option (right to buy)derivative | +125,000 | $0.00 | $0 | 125,000 | 35 d ago |
| Sep 4, 2026 | Raza Bokhari Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +500,000 | $0.00 | $0 | 500,000 | 35 d ago |
| Sep 4, 2026 | Faisal Mehmud Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +250,000 | $0.00 | $0 | 250,000 | 35 d ago |
| Sep 4, 2026 | Carolyn F. Bonner President and CFO | AGrant or award Stock Option (right to buy)derivative | +250,000 | $0.00 | $0 | 250,000 | 35 d ago |
| Sep 4, 2026 | Edward J. Brennan Chief Scientific Officer | AGrant or award Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | 35 d ago |
| Jun 3, 2026 | Larry Kaiser director | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jun 4, 2026 |
| Jun 3, 2026 | Patrick J Mahaffy director | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jun 4, 2026 |
| Jun 3, 2026 | Sara R. May director | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jun 4, 2026 |
| Jun 3, 2026 | Ajay Raju director | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jun 4, 2026 |
| Jun 3, 2026 | Cathy McMorris Rodgers director | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jun 4, 2026 |
| Jun 3, 2026 | William Ashton director | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jun 4, 2026 |
| Jun 3, 2026 | Andrew Alasdair Smith Chief Operating Officer | AGrant or award Stock Option (right to buy)derivative | +200,000 | $0.00 | $0 | 200,000 | Jun 4, 2026 |
| Jun 3, 2026 | Faisal Mehmud Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +250,000 | $0.00 | $0 | 250,000 | Jun 4, 2026 |
| Jun 3, 2026 | Raza Bokhari Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +500,000 | $0.00 | $0 | 500,000 | Jun 4, 2026 |
| Jun 3, 2026 | Carolyn F. Bonner President and CFO | AGrant or award Stock Option (right to buy)derivative | +250,000 | $0.00 | $0 | 250,000 | Jun 4, 2026 |
| Jun 3, 2026 | Barry Fishman director | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jun 4, 2026 |
| Jun 3, 2026 | Edward J. Brennan Chief Scientific Officer | AGrant or award Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Jun 4, 2026 |
| Jun 3, 2026 | Robert J. Ciaruffoli director | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jun 4, 2026 |
| Mar 30, 2026 | Faisal Mehmud Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Apr 1, 2026 |
| Mar 30, 2026 | Ajay Raju director | AGrant or award Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Apr 1, 2026 |
| Mar 30, 2026 | Cathy McMorris Rodgers director | AGrant or award Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Apr 1, 2026 |
| Mar 30, 2026 | Andrew Alasdair Smith Chief Operating Officer | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Apr 1, 2026 |
| Mar 30, 2026 | Sara R. May director | AGrant or award Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Apr 1, 2026 |
| Mar 30, 2026 | William Ashton director | AGrant or award Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Apr 1, 2026 |
| Mar 30, 2026 | Raza Bokhari Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +325,000 | $0.00 | $0 | 325,000 | Apr 1, 2026 |
| Mar 30, 2026 | Carolyn F. Bonner President and CFO | AGrant or award Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Apr 1, 2026 |
| Mar 30, 2026 | Edward J. Brennan Chief Scientific Officer | AGrant or award Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Apr 1, 2026 |
| Mar 30, 2026 | Robert J. Ciaruffoli director | AGrant or award Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Apr 1, 2026 |
| Mar 30, 2026 | Barry Fishman director | AGrant or award Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Apr 1, 2026 |
| Mar 30, 2026 | Larry Kaiser director | AGrant or award Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Apr 1, 2026 |
| Mar 30, 2026 | Patrick J Mahaffy director | AGrant or award Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Apr 1, 2026 |
| Dec 16, 2025 | William Ashton director | AGrant or award Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Dec 18, 2025 |
| Dec 16, 2025 | Raza Bokhari Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Dec 18, 2025 |
| Dec 16, 2025 | Carolyn F. Bonner President and CFO | AGrant or award Stock Option (right to buy)derivative | +75,000 | $0.00 | $0 | 75,000 | Dec 18, 2025 |
| Dec 16, 2025 | Edward J. Brennan Chief Scientific Officer | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Dec 18, 2025 |
| Dec 16, 2025 | Robert J. Ciaruffoli director | AGrant or award Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Dec 18, 2025 |
| Dec 16, 2025 | Barry Fishman director | AGrant or award Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Dec 18, 2025 |
| Dec 16, 2025 | Larry Kaiser director | AGrant or award Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Dec 18, 2025 |
| Dec 16, 2025 | Patrick J Mahaffy director | AGrant or award Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Dec 18, 2025 |
| Dec 16, 2025 | Sara R. May director | AGrant or award Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Dec 18, 2025 |
| Dec 16, 2025 | Faisal Mehmud Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +75,000 | $0.00 | $0 | 75,000 | Dec 18, 2025 |
| Dec 16, 2025 | Ajay Raju director | AGrant or award Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Dec 18, 2025 |
| Dec 16, 2025 | Cathy McMorris Rodgers director | AGrant or award Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Dec 18, 2025 |
| Dec 16, 2025 | Andrew Alasdair Smith Chief Operating Officer | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Dec 18, 2025 |
| Aug 13, 2025 | James P. Quinlan Chief Financial Officer | MOption exercise Common Shares, no par value ("Common Shares") | +125,000 | $0.81 | $101k | 254,147 | Aug 14, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- William Ashtondirector
- Raza BokhariChief Executive Officer
- Carolyn F. BonnerPresident and CFO
- Edward J. BrennanChief Scientific Officer
- Robert J. Ciaruffolidirector
- Barry Fishmandirector
- Larry Kaiserdirector
- Patrick J Mahaffydirector
- Sara R. Maydirector
- Faisal MehmudChief Medical Officer
- James P. QuinlanChief Financial Officer
- Ajay Rajudirector, owner
- Cathy McMorris Rodgersdirector
- Andrew Alasdair SmithChief Operating Officer
- Velocity Fund Partners, LPowner
Questions about MDCX
Answered from the filings on this page, as of the latest one.
Are insiders buying MDCX?
No. In the last 90 days no insider at Medicus Pharma Ltd. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade MDCX on the open market?
Velocity Fund Partners, LP (10% owner) sold $579k of MDCX on May 20, 2025 and filed the Form 4 on May 21, 2025. InsiderTell scored 31 (weak).
How many insiders file Form 4 at Medicus Pharma Ltd.?
15 people have filed a Form 4 at Medicus Pharma Ltd., among them William Ashton (director), Raza Bokhari (Chief Executive Officer), Carolyn F. Bonner (President and CFO). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.